Long‐term cannabidiol treatment in patients with Dravet syndrome: An open‐label extension trial

OBJECTIVE: Add‐on cannabidiol (CBD) significantly reduced seizures associated with Dravet syndrome (DS) in a randomized, double‐blind, placebo‐controlled trial: GWPCARE1 Part B (NCT02091375). Patients who completed GWPCARE1 Part A (NCT02091206) or Part B, or a second placebo‐controlled trial, GWPCAR...

Descripción completa

Detalles Bibliográficos
Autores principales: Devinsky, Orrin, Nabbout, Rima, Miller, Ian, Laux, Linda, Zolnowska, Marta, Wright, Stephen, Roberts, Claire
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Full‐length Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7379690/
https://www.ncbi.nlm.nih.gov/pubmed/30582156
http://dx.doi.org/10.1111/epi.14628

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7379690/
https://www.ncbi.nlm.nih.gov/pubmed/30582156
http://dx.doi.org/10.1111/epi.14628

Ejemplares similares